Full Text View
Tabular View
No Study Results Posted
Related Studies
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
This study has been completed.
Study NCT00301964   Information provided by National Cancer Institute (NCI)

First Received on March 9, 2006.   Last Updated on January 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Recurrent Endometrial Carcinoma
Additional conditions recognized in this trial
Adenoma
Carcinoma
Endometrial Neoplasms
More general conditions related to this trial
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Uterine Diseases
Uterine Neoplasms
Interventions listed in this trial
bevacizumab
laboratory biomarker analysis
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services